Polycystic Ovary Syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Consumption material: Propolis
Chemical composition and concentration: Different types of Flavonoids, Cinnamic acid derivatives, 50% plant gum or resin, 30% wax, 10% essential fatty acids, 5% pollen, and 5% organic compounds, vitam
Dosage: 300 mg per day
How to use: orally
Manufacturer: Shahdineh Golha Company. Intervention 2: Control group: Consumption material: Avicel
Chemical composition: Cellulose microcrystalline
Manufacturer: Pishgaman Shimi.
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Having Polycystic ovary syndrome according to Rotterdam criteria Body mass index (BMI) greater than or equal to 18.5 kg/m2
Exclusion criteria
Exclusion criteria: Pregnancy Lactation Insulin injection People with autoimmune diseases People with gastrointestinal diseases People with liver disease People with thyroid disease People with cardiovascular disease People with severe respiratory illness such as asthma and chronic bronchitis Consume any vitamins, minerals and dietary supplements Existence of allergies to Propolis, Honey and bee products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High-sensitivity C-reactive Protein. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Enzyme-Linked Immunosorbent Assay.;Insulin Resistance Index. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: HOMA-IR={[Fasting insulin (microunits/ml)] × [Fasting Glucose (mmol/l)]}/22.5.;Free androgen index. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Free androgen index = 100 X [(Total Testosterone)/Sex hormone binding globulin]. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body mass index. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Body mass index=body mass (kg)/ the square of the body height (m).;Omentin-1. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Enzyme-Linked Immunosorbent Assay.;Chemerin. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Enzyme-Linked Immunosorbent Assay.;Neopterin. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Enzyme-Linked Immunosorbent Assay.;Testosterone. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Enzyme-Linked Immunosorbent Assay.;Follicle-stimulating hormone. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Enzyme-Linked Immunosorbent Assay.;Luteinizing hormone. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Enzyme-Linked Immunosorbent Assay.;Dehydroepiandrosterone. Timepoint: At the beginning of the study (before the intervention) and at the end of the study. Method of measurement: Enzyme-Linked Immunosorbent Assay. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Saber
Kermanshah University of Medical Sciences
Outcome results
None listed